Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes

Molecular Diagnosis and Therapy

Volumn 14, Issue 3, 2010, Pages 171-178

  Fonseca, Francina ^a   Gratacòs, Mònica ^b   Escaramís, Geòrgia ^b   De Cid, Rafael ^b,c   Martín Santos, Rocío ^d,e   Fernnádez Espejo, Emilio ^f   Estivill, Xavier ^b,c,g   Torrens, Marta ^a,h  

^a Institut de Neuropsiquiatria i Addiccions (INAD) Parc de Salut Mar   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^f UNIVERSITY OF SEVILLE   (Spain)

^g UNIVERSITAT POMPEU FABRA   (Spain)

^h UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Clinical genetics; Heroin abuse; Methadone, general; Pharmacogenetics; Substance related disorders

Indexed keywords

METABOTROPIC RECEPTOR 6; METABOTROPIC RECEPTOR 8; METHADONE; MYOCARDIN; OPIATE RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; COGNITIVE DEFECT; CONTROLLED STUDY; DEMOGRAPHY; DRUG ABUSE; DRUG DEPENDENCE; ETHNICITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS;

ADULT; AGED; ALLELES; ANALGESICS, OPIOID; FEMALE; GENOTYPE; HUMANS; MALE; METHADONE; MIDDLE AGED; NUCLEAR PROTEINS; OPIOID-RELATED DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, METABOTROPIC GLUTAMATE; TRANS-ACTIVATORS; YOUNG ADULT;

EID: 77954114982     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11537650-000000000-00000     Document Type: Article

References (30)

1. Kreek MJ, Zhou Y, Butelman ER, et al. Opiate and cocaine addiction: from bench to clinic and back to the bench. Curr Opin Pharmacol 2009 Feb; 9 (1): 74-80
2. Nielsen DA, Ji F, Yuferov V, et al. Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry 2008 Apr; 13 (4): 417-428
3. Amato L, Davoli M, Perucci CA, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005 Jun; 28 (4): 321-329
4. Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 2008; 34 (4): 355-381
5. Li Y, Kantelip JP, Gerritsen-van Schieveen P, et al. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 2008; 12 (2): 109-124
6. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006 Dec; 80 (6): 668-681
7. Levran O, O'Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008 Jul 15; 17 (14): 2219-2227
8. Barratt DT, Coller JK, Somogyi AA. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet B Neuropsychiatr Genet 2006 Jun 5; 141B (4): 323-331
9. Crettol S, Besson J, Croquette-Krokar M, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008 Oct 1; 32 (7): 1722-1727
10. de CidR, Fonseca F, GratacosM, et al. BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav 2008 Jul; 7 (5): 515-522
11. Doehring A, Hentig N, Graff J, et al. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics 2009 Jun; 19 (6): 407-414
12. Torrens M, Serrano D, Astals M, et al. Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 2004 Jul; 161 (7): 1231-1237
13. Gonzalez F, Salvador L, Martinez JM, et al. Estudio de fiabilidad y validez de la versió n española de la entrevista clý nica Addiction Severity Index (ASI). In: Iraurgi I, Gonzalez F, editors. Instrumentos de evaluació n en drogodependencias. Madrid: Aula Medica Ediciones; 2002: 271-308
14. Gonzalez JR, Armengol L, Sole X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007 Mar 1; 23 (5): 644-645
15. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009 Aug; 10 (8): 561-572
16. Lavreysen H, Dautzenberg FM. Therapeutic potential of group III metabotropic glutamate receptors. Curr Med Chem 2008; 15 (7): 671-684
17. Hasin D, Liu X, Nunes E, et al. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry 2002 Apr; 59 (4): 375-380
18. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001 Feb; 2 (2): 119-128
19. Kelley AE. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 2004 Sep 30; 44 (1): 161-179
20. Pipes GC, Creemers EE, Olson EN. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev 2006 Jun 15; 20 (12): 1545-1556
21. Chow N, Bell RD, Deane R, et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci U S A 2007 Jan 16; 104 (3): 823-828
22. Falcon E, McClung CA. A role for the circadian genes in drug addiction. Neuropharmacology 2009; 56 Suppl. 1: 91-96
23. Kosobud AE, Gillman AG, Leffel 2nd JK, et al. Drugs of abuse can entrain circadian rhythms. Scientific World J 2007 Nov 2; 7: 203-212
24. Petrzilka S, Taraborrelli C, Cavadini G, et al. Clock gene modulation by TNFalpha depends on calcium and p38 MAP kinase signaling. J Biol Rhythms 2009 Aug; 24 (4): 283-294
25. Fernandez-Espejo E, Ramiro-Fuentes S, Rodriguez de Fonseca F. The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience 2009 Dec 1; 164 (2): 667-675
26. Niwa M, Nitta A, Yamada K, et al. The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor-alpha, and an inducer of these factors in drug dependence. J Pharmacol Sci 2007 Jun; 104 (2): 116-121 (Pubitemid 46974984)
27. Reynolds KK, Ramey-Hartung B, Jortani SA. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. Clin Lab Med 2008 Dec; 28 (4): 581-598
28. WuWD, Wang Y, Fang YM, et al. Polymorphism of themicro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery. Mol Diagn Ther 2009; 13 (5): 331-337
29. Farre M, Mas A, Torrens M, et al. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002 Feb 1; 65 (3): 283-290
30. Simpson DD. Treatment for drug abuse: follow-up outcomes and length of time spent. Arch Gen Psychiatry 1981 Aug; 38 (8): 875-880